Adaptive Radiation Treatment for Head and Neck Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

September 7, 2012

Primary Completion Date

December 1, 2021

Study Completion Date

December 24, 2024

Conditions
Head and Neck Cancer
Interventions
DRUG

cisplatinum

i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy

RADIATION

Conventional radiotherapy

conventional radiotherapy, 70Gy in 7 weeks

RADIATION

Adaptive radiotherapy

adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks

Trial Locations (9)

17177

Karolinska Institute, Stockholm

94800

Gustave Roussy Cancer Institute, Villejuif

1066CX

Netherlands Cancer Institute, Amsterdam

9713 GZ

Universitair Medisch Centrum Groningen, Groningen

NL-6229 ET

Maastro Clinic, Maastricht

3075 EA

Erasmus Medical Centre, Rotterdam

NL-3508GA

University Medical Centre Utrecht, Utrecht

08035

University Hospital Vall d'Hebron, Barcelona

M20 5BX

Christie Hospital NHS Trust, Manchester

All Listed Sponsors
collaborator

Karolinska Institutet

OTHER

collaborator

Maastricht Radiation Oncology

OTHER

collaborator

Institut Catala de Salut

OTHER_GOV

collaborator

The Christie NHS Foundation Trust

OTHER

collaborator

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

collaborator

UMC Utrecht

OTHER

collaborator

European Union

OTHER

lead

The Netherlands Cancer Institute

OTHER

NCT01504815 - Adaptive Radiation Treatment for Head and Neck Cancer | Biotech Hunter | Biotech Hunter